News

YOSPRALA is indicated for patients who require aspirin for secondary prevention of cardiovascular (CV) and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers.

The drug was studied in patients with type 2 diabetes (T2D) in combination with sitagliptin and metformin. The double-blind, placebo-controlled phase 3 VERTIS SITA2 trial randomized 463 subjects

People who received the two-dose Shingrix vaccine had an 88% lower risk of developing shingles in the fourth year after vaccination, compared with a 91% reduction over the entire

The study achieved its primary efficacy endpoint demonstrating statistical superiority over each of its components, including Aerie product candidate Rhopressa (netarsudil ophthalmic solution) 0.02%, and market leading prostaglandin analogue

CUVITRU is a treatment for patients with primary immunodeficiency (PI), a group of more than 300 genetic disorders in which part of the body’s immune system is missing

Depression is one of the most common mental health disorders in the United States, as an estimated one in 15 adults (6.7%) experience at least one major depressive

Vitae discovers and develops small molecule drugs for diseases with significant unmet medical needs. The company uses its structure-based drug design platform, Contour, for discovering a portfolio of

Pharmatek, founded in 1999, offers dosage form development and clinical-scale cGMP manufacturing of oral, injectable and topical products for over 100 customers globally. The acquisition will add discovery-to-clinic

These two large outcome trials will help to define the potential role of dapagliflozin in the management of chronic kidney disease and chronic heart failure respectively, in people